Basel, 8 January 2014 -- Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models1. Roche Pharma Early Research and Development (pRED) scientists found that such enhanced transfer of antibodies through the BBB was associated with a marked improvement in amyloid reduction in the brain of a mouse model of Alzheimer’s disease.
“Thanks to our sophisticated protein engineering we were able to design a system that exploits natural transport mechanisms to significantly increase the transfer of investigational antibodies into the brain in preclinical models,” said Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche pRED. “Using Roche’s Brain Shuttle technology, the target engagement of investigational antibodies in the brain in a preclinical model was increased by over 50-fold compared to the parent antibody.”
The BBB is a selective interface that restricts movement of molecules between the bloodstream and central nervous system. This barrier imposes a major challenge to the development of therapies for neurological diseases, in particular large molecules, due to the limited ability with which they can penetrate through the BBB. The study published in Neuron showed that the Roche Brain Shuttle acts by engaging the natural transferrin receptor (TfR) in a specific mode that triggers a process called receptor-mediated transcytosis to transport molecules into the brain.
“The efficacy of the Brain Shuttle technology in preclinical models suggests that this approach could deliver therapeutic molecules across the BBB. We will continue to investigate the potential of the Brain Shuttle technology to transport a variety of molecules such as growth factors, antibodies, peptides and oligonucleotides across the BBB,” said Anirvan Ghosh, Head Neuroscience Discovery at Roche pRED.
“If we are able to clinically validate the preclinical results observed with the Brain Shuttle technology, it could lead us to a way to test investigational drugs in a variety of brain disorders,” said Per-Ola Freskgard, the Preclinical Project Leader for this technology platform at Roche pRED.
About Neuroscience
Roche is working on developing molecular entities in neuroscience for a range of diseases including schizophrenia, multiple sclerosis, depression, neurodevelopmental disorders, Parkinson’s disease and Alzheimer’s disease. With one of the strongest neuroscience pipelines in the industry, and by working closely with academic institutions, biotech companies, and forming public-private partnerships, Roche’s focus is on expanding its Neuroscience franchise to better serve patients.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, infectious disease, inflammation metabolism and neuroscience. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012, Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs ($9 billion US) in R&D. The Group posted sales of 45.5 billion Swiss francs ($48.4 billion US). Genentech, United States, is a wholly owned member of the Roche Group. Roche is the majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com .
Help employers find you! Check out all the jobs and post your resume.
